Introduction
Adenovirus vectors (Ads) have been employed for a wide variety of cancer gene therapy applications to date. This utility has derived principally from the unparalleled ability of these agents to accomplish efficient gene delivery to tumor targets in vivo, as demonstrated in various animal models of locoregional disease. 1 Unfortunately, translation of these advantages has been more difficult to accomplish in human clinical gene therapy trials for cancer. This fact derives from key determinants relevant to both vector and host biology. In the first instance, it has been recognized that tumor cells manifest a relative deficiency of the primary adenoviral receptor, coxsackievirus and adenovirus receptor (CAR). [1] [2] [3] This CAR deficiency renders tumor cells resistant to Ad, thus limiting the therapeutic advantages of this vector in the context of human use. On the basis of this biologic consideration, strategies to alter Ad tropism have been endeavored to allow CAR-independent target cell infection as a means to improve vector potency. 1, [4] [5] [6] [7] [8] [9] [10] In addition, Ad localizing within the systemic circuit exhibits a marked hepatotropism. In this regard, it has been demonstrated that intratumorally administered Ad which escapes the locoregional context localizes principally to the liver whereby vector-related toxicity may be induced. 11, 12 Further, systemic vector administration schemes directed towards disseminated neoplastic disease are countermanded by the propensity of the vector to be sequestered in the liver. [13] [14] [15] [16] On this basis, Ad tropism modification endeavors have also sought to accomplish an alleviation of Ad hepatotropism as a means to circumvent the potential for vector-related toxicities and as a means to potentially advance vector design towards utility for disseminated disease.
Adaptation of Ad for cancer gene therapy applications would thus ideally embody these two mandates -the ability to accomplish CAR-independent gene delivery as a means to improve vector efficiency for tumor targets and the ability to avoid liver sequestration as a means to limit potential vector-related toxicities. Herein, we report an initial strategy to achieve these linked goals and thereby improve the utility of Ad for cancer gene therapy applications. The strategy we report allows address of both of these requirements, in part, such that an improvement of the relative preferentiality of gene transfer to tumor targets is achieved. Such improvements of targetto-background gene transfer may represent the most relevant predicates with respect to improving the therapeutic index of the various Ad-based cancer gene therapy approaches. Figure 1 shows the schematic design and construction of longer-shafted Ad vectors developed in this study. Derived vectors included Ad5 with wild-type shaft 22 ␤-repeats (Ad5), wild-type shaft plus incorporated HI loop RGD4C (Ad5RGD), an extended shaft 32 ␤-repeats (Ad5long), and extended shaft plus incorporated HI loop RGD4C (Ad5RGDlong).
Results

Generation of longer-shafted Ad vectors
To confirm that the genomes of longer-shafted Ad vectors show the expected structure, we analyzed DNA isolated from viral particles. As shown in Figure 2a , the PCR bands of the complete shaft region of longer-shafted Ad vectors (Ad5long and Ad5RGDlong) appeared at upper positions as expected by genome constructions compared with the wild-type shaft variants (Ad5 and Ad5RGD, upper panel). The PCR bands of the fiber knob HI loop region of RGD4C HI loop variants (Ad5RGD and Ad5RGDlong) also appeared at upper positions as expected by genome constructions relative to the wildtype HI loop variants (Ad5 and Ad5long, lower panel). DNA sequencing for the shaft and the HI loop region showed the expected sequence for both of the longershafted variants (data not shown). (Figure 2b ).
To investigate knob-CAR interaction of longer-shafted Ad vectors, interaction between Ad vectors and recombinant soluble form of truncated CAR-His6-tagged (sCARHis6) protein was examined by solid-phase binding enzyme-linked immunosorbent assay (ELISA). We had already established that sCAR-His6 protein efficiently binds to recombinant Ad5 fiber protein. 17 As shown in Figure 2c , there was no significant difference in binding to sCAR-His6 between longer-shafted Ad vectors and wild-type shaft variants. This result suggests that shaft extension has no impact on knob-CAR interaction, and also suggests that trimer formation or stability of fiber were not changed by extension of the shaft.
Longer-shafted Ad vectors reduce CAR-dependent infectivity but does not affect CAR-independent infectivity in vitro
Longer-shafted Ad vectors were studied with respect to gene transfer physiology. For analysis of the specific gene transfer dynamics of these vectors, we defined a panel of tumor targets characterized by variable levels of the Ad primary receptor CAR. Specifically, flow cytometry analysis demonstrated high levels of CAR characterizing the human tumor cell lines HeLa, LNCaP and A549. Similar analysis defined the human tumor cell lines RD, SK-OV-3, and D65MG as exhibiting low, or absent, levels of CAR ( Figure 3 ).
For the high CAR lines, Ad5long reduced the gene transfer of the control Ad5 (Figure 4 ). This finding is consistent with our previous studies, whereby the fiber shaft extension modification inhibits CAR-mediated gene transfer. 18 For the low CAR cell lines, no difference was noted in the gene transfer efficiency of Ad5long compared with the control Ad5 (Figure 4 ). This result is consistent with the gene transfer efficiency in HeLa cells after blocking knob-CAR interaction by recombinant Ad5 knob protein ( Figure 5 ). These findings reflect the fact that fiber shaft extension is only inhibitory in a high CAR context; the low-level baseline CAR-independent entry pathways of Ad are not perturbed by the shaft extension capsid modification.
Of note, inclusion of the HI loop fiber modification to the Ad with normal fiber shaft length (Ad5RGD) resulted in a dramatic augmentation of gene transfer to the low CAR cellular targets ( Figure 4 ). This is consistent with our previous findings with respect to the utility of augmenting CAR-independent pathways in the setting of low CAR cellular targets. 19 This same fiber knob modification also allowed greatly augmented gene transfer efficiencies via the shaft extended Ad vector (Ad5RGDlong, Figure 4 ). These results are also consistent with the gene transfer efficiency in HeLa cells after blocking knob-CAR interaction by recombinant Ad5 knob protein ( Figure 5 ). It thus appears that whereas fiber shaft extension inhibits gene transfer via CAR-dependent pathways, it does not abrogate the efficiency gains achieved via routing the vector into CAR-independent pathways associated with the RGD4C HI loop modification. These
Figure 2 Generation of longer-shafted Ad vectors. (a) To confirm that the genomes of longer-shafted Ad vectors show the expected structure, DNA isolated from viral particles was analyzed. PCR was performed to amplify the complete fiber shaft region (upper panel) or the fiber knob HI loop region (lower panel). (b) To verify that longer-shafted Ad vectors have the predicted different lengths of fiber proteins, Western blot analysis was performed. Purified Ad virions were boiled and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then were detected with anti-fiber monoclonal antibody (MAb) 4D2. Recombinant Ad5 fiber protein was used as a control. (c) Knob-CAR interaction of longer-shafted Ad vectors was examined by solid-phase binding enzyme-linked immunosorbent assay (ELISA). Purified Ad virions immobilized in the wells of an ELISA plate were incubated with various concentrations of recombinant soluble form of truncated CAR-His6-tagged (sCAR-His6) protein. Binding sCAR-His6 protein was then detected with anti-sCAR-His6 MAb 2A3.
Figure 3 Expression levels of CAR in tumor cell lines. HeLa cells (a), LNCaP cells (b), A549 cells (c), RD cells (d), SK-OV-3 cells (e) and D65MG cells (f) were incubated with anti-CAR (RmcB) or no primary MAb (negative control). Cells were then washed with FACS buffer and incubated with secondary FITC-labeled goat anti-mouse immunoglobulin G serum. After cells were washed with FACS buffer, 10
4 cells per sample were analyzes by flow cytometry. Expression levels of CAR and negative control are shown as bold black line and spike filled in gray, respectively. studies thus validated the achievement of our goal of modifying Ad to inhibit CAR-dependent infection, while augmenting its CAR-independent gene transfer capacity.
Figure 4 Infectivity profiles of longer-shafted Ad vectors in tumor cells in vitro. Gene transfer efficiencies of Ad5, Ad5long, Ad5RGD and Ad5RGDlong were tested in tumor cells expressing variable levels of CAR: HeLa cells (CAR-positive) (a), LNCaP cells (CAR-positive) (b), A549 cells (CAR-positive) (c), RD cells (CAR-negative) (d), SK-OV-3 cells (CAR-negative) (e), and D65MG cells (CAR-negative) (f). All cells were infected
Longer-shafted Ad vectors Ad5long and Ad5RGDlong reduce infectivity in the liver compared with the wildtype Ad5 and Ad5RGD
We next sought to evaluate the in vivo vector gains accrued via the endeavored genetic capsid modifications of Ad. In the first instance, we administered the various Ad species to mice via tail vein injection. As noted, systemic administration of Ad results in >95% of transgene expression in the liver. 14, 16 It has been hypothesized that the basis of this phenomenon is the elevated CAR levels expressed in hepatic parenchymal targets. 20 In consideration of this concept, we hypothesized that the Ad species with extended shaft would exhibit reduced transgene expression in the liver based upon the specific inhibition of CAR-dependent gene transfer associated with this capsid modification. As shown in Figure 6a , it was noted that the extended shaft Ad (Ad5long) was associated with more than one log reduction of gene transfer to the liver compared with the control Ad5 (12.5%, P = 0.0047).
Of note, whereas the RGD4C HI loop modification (Ad5RGD) enhanced overall gene transfer to the liver compared with the control Ad5GL (348%, P = 0.00020), such an enhancement was not noted with the RGD4C modification in the context of the long shaft modification (Ad5RGDlong) compared with the control Ad5GL (83.4%, P = 0.51). It thus appeared that this vector species, which is enhanced for CAR-independent gene transfer capacity, is not associated with enhanced hepatotropism, per se.
Ad5RGDlong retains enhancement of gene transfer for CAR-negative tumors in vivo
As a model of locoregional cancer gene therapy we employed the Ad species for intratumoral infection by direct vector administration. Models were established whereby both high CAR (A549) and low CAR (SK-OV-3) tumor xenografts were implanted as subcutaneous nodules. After intratumoral vector challenge the nodules were harvested and analyzed for the magnitude of A marked enhancement of gene transfer was accomplished for these low CAR targets via the HI loop RGD4C modification (Ad5RGD, Figure 7b and 371%, P = 0.0072). Of note, these augmentations were retained when the RGD4C HI loop modification was presented in the context of an extended fiber shaft (Ad5RGDlong, Figures 7b and 327%, P = 0.0000042).
Discussion
In a previous study we have shown that artificial extension of the adenoviral fiber interrupts key interactions of the vector particle with target cell receptors. 18 These alt- Gene Therapy ered cellular interactions result in inhibition of CARmediated gene transfer to cellular targets. We have also shown previously that the incorporation of the integrin binding peptide RGD4C at the adenovirus fiber knob HI loop enhances CAR-independent gene transfer to target cells, an effect most noteworthy in the context of cells deficient in CAR. 19 In consideration of these distinct tropism alterations, we sought to devise vectors, which contained both modifications -extended fiber shaft length plus RGD4C at the HI loop of fiber. We hypothesized that the specific vector gains accrued with these distinct approaches would operate in an additive manner towards our cancer gene therapy goals. Specifically, the selective inhibition of CAR-dependent gene transfer, in combination with the enhancement of CAR-independent gene transfer, would accomplish enhanced gene delivery to tumor cells and the achievement of the reduced hepatotropism.
The low CAR phenotype characterizing human tumor has predicated the development of strategies to alter Ad tropism towards the goal of achieving CAR-independent gene transfer capacity. Such an endeavor embodies the concept that infectivity-enhanced Ad will circumvent tumor cell vector resistance, allowing improved gene delivery with a more favorable outcome in clinical interventions. On this basis, a variety of genetic capsid modifications has been proposed for the achievement of Ad infectivity enhancement.
1,4-10 Alternatively, ectopic localization of Ad may result in unintended gene transfer to hepatic cells with the consequence of vector-related toxicity. 11, 12, 21 It is thus axiomatic that any infectivity enhancement maneuver does not also results in an increased propensity for liver tropism. On this basis, strategies to mitigate native mechanisms of Ad hepatotropism have likewise been endeavored via genetic capsid modification approaches. These dual considerations thus mandate Ad vector modifications designed to achieve CAR-independent gene transfer for enhanced gene transfer to tumor targets plus mitigation of CAR-dependent hepatic uptake mechanisms. Herein we have proposed a conceptual approach, which addresses these issues. Specifically, the combination of fiber shaft extension plus fiber HI loop incorporation of the RGD4C peptide ligand (Ad5RGDlong) achieves enhancement of tumor cell infection by intratumoral administration (Figure 7b ), while also limiting any enhancement of the capacity of the vector to achieve hepatotropism by the tail vein injection (Figure 6a ). Although these data were obtained from two separate experiments, it is strongly expected that Ad5RGDlong will be able to augment gene transfer capacity for CAR-negative tumors without enhanced hepatotropism in vivo. Such vector design improvements may potentially allow an improved utility of Ad for the current generation of cancer gene therapies directed towards locoregional disease. In addition, further refinements of such specificity goals may allow the practical approach of disseminated disease via systemic vector application.
The concept of altering vector biology at multiple levels for improvement of targeting physiology has recently been explored. In this regard, targeting ligands have been introduced at adenovirus capsid sites in combination with genetic ablation of the CAR recognition domains of the fiber knob. 1, [22] [23] [24] This approach was designed to address the same specific issues we address in the current report: enhancement of target cell infection with ablation of ectopic transgene expression in the liver. In addition to distinct capsid modification steps, it is also feasible to combine distinct mechanisms of targeting. In this regard, Reynolds et al 25 have employed a transcriptional control strategy in combination with the type of transductional targeting approaches, which are the subject of this report. In the aggregate, these studies have highlighted the significant gene therapy outcome gains achievable via directed vector engineering. On this basis, it is likely that even further improvements towards the goal of targeted, cell-specific gene delivery may be accomplished by further combinations of distinct targeting approaches.
Interestingly, infectivity of Ad5RGDlong in A549 was similar to Ad5 (Figures 4c and 7a) . Our flow cytometry assay showed that A549 expressed the highest levels of ␣V integrins (data not shown). We suggest that these elevated levels of ␣V integrins affect Ad5RGDlong which have integrin-dependent gene delivery capacity, and thus minimizing any difference between Ad5RGDlong and Ad5. The altered tropism profile of Ad5RGDlong could theoretically increase the toxicity for lung and kidney compared with Ad5 (Figure 6c and e) . However, systemic administration of Ad results in >95% of transgene expression in the liver. 14, 16 Indeed our results (Figure 6 ) also demonstrated the same pattern. We believe that absolute transgene expression in lung and in kidney are significantly lower compared with transgene expression in the liver; therefore this problem is relatively less than that of hepatotropism of wild-type shaft Ad5 vectors. SK-OV-3 cells were grown in McCoy's 5a Medium containing 10% FCS, 1.5 mM glutamine, and 1.5 g/l sodium bicarbonate. All other cells were maintained in DMEM containing 10% FCS, 2 mM glutamine, and 4.5 g/l glucose. Cells were cultured at 37°C in a 5% CO 2 atmosphere.
Materials and methods
Cells and cell culture
Design and construction of longer-shafted Ad vectors
Construction of longer-shafted Ad vectors used in this study is shown in Figure 1 . According to a triple ␤-spiral model for Ad2 fiber shaft, 26 we made Ad5 capsid-based longer-shafted Ad vectors by incorporating Ad2 shaft fragment into the NheI site located in the 8th ␤-repeat of the Ad5 shaft. In order to generate Ad2 shaft fragment (from the 4th to the 14th ␤-repeat), PCR was performed. Template DNA was purified from Ad2 viral particles obtained from the American Type Culture Collection. The primer sequences used to amplify fragment of Ad2 fiber shaft are as follows: PLup (nucleotides (nt) 31312 to 31341; 5'-TCAAACCTAGGTTTGGACACCTCCGCA CCA-3') and PLdown (nt 31788 to 31759; 5'-AATTCC TAGGTTGTTTGATGAATCATAACC-3').
Nucleotide numbers are according to the sequences obtained from GenBank (accession No. J01917). Each 5' end of primer was modified to create restriction enzyme site for AvrII. This fragment was cloned into the NheI digested pNEB.PK.FSP (Ad5 fiber shuttle vector) 27 or pNEB.PK.F HI RGD (Ad5RGD fiber shuttle vector which contained Arg-Gly-Asp peptide in the HI loop of the fiber knob). 19 The resultant plasmids were digested with PacI and KpnI, and were used for homologous DNA recombination with SwaI-linearized pVK50-based backbone plasmids. 6 The pVK50-based backbone plasmid contains cytomegalovirus (CMV) promoter-driven green fluorescent protein (GFP) gene and CMV promoter-driven firefly luciferase (LUC) gene-expressing cassette in the E1 region of Ad5 genome. After homologous DNA recombination, these plasmids were linearized with PacI and transfected into 293 cells to generate Ad vectors. The resulting longer-shafted Ad vectors have a total of 32 ␤ -repeats. As shown in our previous study, these viruses have the longest shaft length which we can rescue by our current technology. 18 Ad vectors which contain longershaft were designated by suffix 'long' and Ad vectors which contain an RGD4C motif in the HI loop of the fiber knob were designated by suffix 'RGD'. All Ad vectors were propagated on 293 cells and purified by double centrifugation in CsCl gradients by a standard protocol. Determination of virus particle (VP) titer was accomplished spectrophotometrically by the method of Maizel et al 28 using a conversion factor of 1.1 × 10 12 VPs per absorbance unit at 260 nm. To determine whether the genomes of longer-shafted Ad vectors indeed show the expected structure, PCR and DNA sequencing were performed. The primer sequences used to amplify and sequence the complete fiber shaft region or the fiber knob HI loop region are as follows: PSup (nt 31114 to 31143; 5'-ACTGTGCCTTTTCTTACTCCTCCCTTTGTA-3'), PS down (nt 32277 to 32248; 5'-TCTACAGTTAGGAGAT GGAGCTGGTGTGGT-3'), PHIup (nt 32516 to 32535; 5'-CAAACGCTGTTGGATTTATG-3'), and PHIdown (nt 32762 to 32742; 5'-GTGTAAGAGGATGTGGCAAAT-3'). Nucleotide numbers are according to the sequences obtained from GenBank (accession No. M73260).
Western blot analysis
To confirm that longer-shafted Ad vectors have different lengths of fiber proteins, Western blot analysis was performed by the method as previously described. 18 Purified Ad virions (Ad5, Ad5long, Ad5RGD, or Ad5RGDlong) were diluted in Laemmli sample buffer (BioRad, Hercules, CA, USA). Each sample was boiled and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After electrophoretic transfer to polyvinylidene difluoride membrane (BioRad), the blot was probed mouse anti-fiber monoclonal antibody (MAb) 4D2. Bound mouse anti-fiber MAb 4D2 was detected with secondary goat anti-mouse IgG conjugated to alkaline phosphatase (Sigma, St Louis, MO, USA). A 0.5 g standard of recombinant Ad5 fiber protein 17 was included for comparison to the proteins in the sample. Mouse MAb 4D2 directed against the tail domain of Ad5 fiber protein was generated at the University of Alabama at Birmingham Hybridoma Core Facility.
17,29
ELISA Solid-phase binding enzyme-linked immunosorbent assay (ELISA) was performed by the method as previously described. 18, 30 Purified Ad virions (Ad5, Ad5long, Ad5RGD, or Ad5RGDlong) were diluted in 50 mM carbonate buffer (pH 9.6) to a concentration of 10 10 VP/ml, and 100 l aliquots were immobilized on 96-well NuncMaxisorp ELISA plate by overnight incubation. Purified recombinant soluble form of truncated CAR-His6-tagged protein (sCAR-His6) 17 was diluted in binding buffer (phosphate-buffer saline (PBS; pH 7.4) with 0.05% Tween 20 and 0.5% bovine serum albumin (BSA)) to concentrations ranging from 12 to 3000 ng/ml. The 100 l dilutions were added to the wells. Bound sCAR-His6 protein was detected with mouse anti-sCAR-His6 MAb 2A3. Bound mouse anti-sCAR-His6 MAb 2A3 was detected with goat anti-mouse IgG conjugated to alkaline phosphatase (Sigma). The plate was then developed with pnitrophenyl phosphate (Sigma) as recommended by the manufacturer. Plates were read in a microtiter plate reader set at 405 nm. Recombinant sCAR-His6 protein was expressed in High Fives cells (Invitrogen, Carlsbad, CA, USA) infected with recombinant baculovirus by the method as previously described. 17 Mouse MAb 2A3 directed against baculovirus-produced human sCARHis6 protein was generated at the University of Alabama at Birmingham Hybridoma Core Facility. 17 
Flow cytometry
Flow cytometry assay was performed by the method as previously described. 30 Tumor cells (HeLa, LNCaP, A549, RD, SK-OV-3, and D65MG) were released from the flasks by the addition of EDTA and resuspended in FACS buffer (PBS (pH 7.4) with 0.1% sodium azide and 1% BSA) at a concentration of 2 × 10 6 cells/ml. Two hundred thousand cells were incubated with RmcB (anti-CAR) or no primary MAb (negative control) at a concentration of Gene Therapy 5 g/ml for 1 h at 4°C. Cells were then washed with FACS buffer and incubated with secondary fluorescein isothiocyanate (FITC)-labeled goat anti-mouse immunoglobulin G serum (Jackson Laboratories, West Grove, PA, USA) at a concentration of 5 g/ml for 1 h at 4°C. After cells were washed with FACS buffer, 10 4 cells per sample were analyzed by flow cytometry at the University of Alabama at Birmingham FACS Core Facility. Data were expressed as the geometric mean fluorescence intensity of the entire gated population. The positive population cells were determined by gating the right-hand tail of the distribution of the negative control sample for each cell line at 1%. The MAb RmcB was purchased from American Type Culture Collection.
In vitro gene transfer assay
Tumor cells (HeLa, LNCaP, A549, RD, SK-OV-3 and D65MG) were seeded in 96-well plates in triplicate at 1 × 10 4 /well the day before infection. After washing with PBS, cells were infected with Ad5, Ad5long, Ad5RGD, or Ad5RGDlong at 10 1 , 10 2 and 10 3 VPs/cell in 2% FCS medium at 37°C for 3 h. The unbound viruses were washed away with PBS, and 10% FCS medium was added. After incubation at 37°C for 48 h, the infected cells were washed again with PBS and lysed by using a passive lysis buffer (Promega, Madison, WI, USA). Luciferase activity in the cell lysates were determined by using a luciferase assay system kit (Promega) and a luminometer (Berthold, Gaithersburg, MD, USA), and normalized by protein concentration in the cell lysates by using a DC protein assay kit (BioRad) with BSA as the standard.
The blocking experiment by recombinant Ad5 knob protein was performed similarly. HeLa cells were preincubated for 10 min at room temperature in 2% FCS medium with or without recombinant Ad5 fiber knob protein at 100 g/ml, and then exposed for 30 min at room temperature to Ad5, Ad5long, Ad5RGD, or Ad5RGDlong in 2% FCS medium at 10 1 , 10 2 , or 10 3 VPs/cell. HeLa cells were washed with PBS and unbound viruses were aspirated, and 10% FCS medium was added. After incubation at 37°C for 30 h, luciferase activity was measured.
In vivo gene transfer assay
In order to determine gene transfer efficiency in mouse organs, balb/c (Charles River Laboratories, Wilmington, MA, USA) mice received 1 × 10 10 VPs of Ad5, Ad5long, Ad5RGD, or Ad5RGDlong via tail vein injection (five mice per group). Two days later, liver, spleen, lung, heart and kidney were harvested for measurement of luciferase gene expression.
Subcutaneous tumors were induced by injection of 5 × 10 6 A549 cells or 1 × 10 7 SK-OV-3 cells into the flank of the congenitally athymic nude mice (Charles River). When tumor formation was confirmed (4-6 mm in diameter), 1 × 10 7 VPs of Ad5, Ad5long, Ad5RGD, or Ad5RGDlong were injected into these tumors (five mice per group). Two days later, mice were killed, and tumors were resected for measurement of luciferase gene expression.
After washing with PBS, tissues were immediately frozen in ethanol/dry ice. Frozen tissues were ground to a fine powder by using a pestle and mortar immersed in an ethanol/dry ice bath. Tissue powder was lysed by using a passive lysis buffer (Promega), and then lucifer-ase activity in the tissue lysates was determined by using a luciferase assay system kit (Promega) and a luminometer (Berthold). Luciferase activity was normalized by protein concentration in the tissue lysate by using a DC protein assay kit (BioRad) with BSA as the reference.
Statistical analysis
Statistical comparisons among groups were assessed with Student's t test (Microcal, origin version 6).
